Target intelligence / Profile preview

Systemic inflammatory cytokine network

Molecular classification
Cytokine, Signaling protein, Soluble mediator
01

Overview

The systemic inflammatory cytokine network is a sophisticated communication system composed of various signaling proteins, including interleukins, interferons, and tumor necrosis factors, that regulate the immune system's response to pathogens and tissue damage (Fajgenbaum & June, 2020, NEJM). This network operates through complex feedback loops where cytokines can induce or inhibit the production of one another, ensuring a balanced inflammatory response (Dinarello, 2000, Chest). Pathological overactivation of this network, often termed a 'cytokine storm,' is a hallmark of severe conditions such as sepsis, CAR-T cell therapy-induced cytokine release syndrome, and severe viral infections (Tanaka et al., 2014, CSH Perspect Biol). Pharmacological strategies do not target the network as a single entity but rather focus on specific high-impact nodes, such as IL-6 or TNF-alpha, to alleviate systemic inflammation (Choy, 2012, Nat Rev Rheumatol). Understanding the temporal and spatial dynamics of this network is crucial for developing precision therapies that can resolve inflammation while preserving essential immune functions (Schett et al., 2013, Nat Rev Immunol).

Other names
Cytokine networkInflammatory cascadeCytokine milieuSystemic inflammatory response mediators
02

Mechanism of action

Modulation of the network occurs through the inhibition of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-1) or their receptors, as well as the inhibition of downstream intracellular signaling pathways like the JAK/STAT pathway (Choy, 2012, Nat Rev Rheumatol; Schett et al., 2013, Nat Rev Immunol).

03

Biological functions

Immune responseInflammationSignal transductionCell-cell communicationHematopoiesis
04

Disease associations

SepsisCytokine release syndromeRheumatoid arthritisSystemic inflammatory response syndromeCOVID-19Autoimmune disease
05

Safety considerations

Increased susceptibility to opportunistic infectionsReactivation of latent tuberculosisNeutropeniaInfusion reactionsImmunosuppression
06

Interacting drugs

Infliximab

6 more in the full profile.

07

Biomarkers

C-reactive protein (CRP)Interleukin-6 (IL-6)Tumor necrosis factor-alpha (TNF-alpha)ProcalcitoninFerritinD-dimer

Beyond the preview

Go deeper on Systemic inflammatory cytokine network.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Systemic inflammatory cytokine network.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call